Program
bretisilocin
A development code. Also written as “GM-2505”.
In AbbVie’s pipeline, Serotonin 5-HT2A receptor
. Its studies are mostly in Depressive Disorder, Major, led by AbbVie.
Furthest: phase 2, since Jan 23, 20241 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 10 open or running | phase 2since Jan 23, 2024 | Jan 23, 2024 | none ahead |
- Named in AbbVie’s own pipeline as
Bretisilocin
, phase 2, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2024First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT06236880 · 126 enrolled · United Kingdom
TargetBeta
“Serotonin 5-HT2A receptor”the company's pipeline, read by Claude · source
Other programs on HTR2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| cyclobenzaprinerule | Tonix Pharmaceuticals | phase 4 | 32 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
| Psilocybinrule | compass-pathways | phase 3 | 22 |
| Trazodonerule | Angelini Pharma | phase 3 | 14 |
| bretisilocin | AbbVie | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06236880Depressive Disorder, Major · United Kingdom | 2 | Completed | Jul 27, 2026 | 126 |
How it is read
Names in the registry
- “GM-2505”, 1 entry
Codes read as this program: GM2505.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.